Bacillus thuringiensis subsp. israelensis (Bti) is increasingly used worldwide for mosquito control and is the only larvicide used in the French Rhône-Alpes region since decades. The artificial selection of mosquitoes with field-persistent Bti collected in breeding sites from this region led to a moderate level of resistance to Bti, but to relatively high levels of resistance to individual Bti Cry toxins. Based on this observation, we developed a bioassay procedure using each Bti Cry toxin separately to detect cryptic Bti-resistance evolving in field mosquito populations. Although no resistance to Bti was detected in none of the three mosquito species tested (Aedes rusticus, Aedes sticticus and Aedes vexans), an increased tolerance to Cry4Aa (3.5-fold) and Cry11Aa toxins (8-fold) was found in one Ae. sticticus population compared to other populations of the same species, suggesting that resistance to Bti may be arising in this population. This study confirms previous works showing a lack of Bti resistance in field mosquito populations treated for decades with this bioinsecticide. It also provides a first panorama of their susceptibility status to individual Bti Cry toxins. In combination with bioassays with Bti, bioassays with separate Cry toxins allow a more sensitive monitoring of Bti-resistance in the field.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970644 | PMC |
http://dx.doi.org/10.1590/0074-0276130155 | DOI Listing |
Malar J
December 2024
Malaria and Neglected Tropical Disease, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Background: Ethiopia faces several severe challenges in terms of malaria elimination, including drug resistance and diagnostic evasion in the Plasmodium falciparum parasite, insecticide resistance in the primary Anopheles malaria vector, and, most recently, the invasion of the Asian malaria vector Anopheles stephensi. Novel malaria control methods are therefore needed, and in this paper, we describe the evaluation of a larval source management (LSM) strategy implemented in response to An. stephensi.
View Article and Find Full Text PDFParasit Vectors
November 2024
University of Pavia, Pavia, Italy.
Background: The biological larvicide Bacillus thuringiensis subsp. israelensis (Bti) represents a safe and effective alternative to chemical insecticides for mosquito control. Efficient control of mosquitoes implicates continuous and extensive application of Bti.
View Article and Find Full Text PDFInfect Drug Resist
October 2024
School of Medicine, University of Electronic Science and Technology of China, Chengdu, People's Republic of China.
Purpose: We analyzed the pathogenic bacteria and antibiotic resistance distributions in patients with biliary tract infections (BTI) using samples from the Antimicrobial Resistant Investigation Network of Sichuan Province (ARINSP) to promote the rational use of antibiotics to reduce multidrug resistance.
Patients And Methods: Participating hospitals identified isolates between 2017 and 2023 and conducted antimicrobial susceptibility tests. Isolated bacteria were identified and tested for drug sensitivity using MOLDI-TOF mass spectrometry system, VITEK automated drug sensitivity system and paper diffusion method, and the results were interpreted with reference to CLSI M100 30th edition standards.
J Microbiol Biotechnol
November 2024
National Research Laboratory of Molecular Microbiology and Toxicology, Department of Agricultural Biotechnology, Seoul National University, Seoul 08826, Republic of Korea.
, an opportunistic human pathogen, employs biofilm formation as a key survival and virulence mechanism. BrpT, a transcriptional regulator, is essential for biofilm development by regulating the expression of biofilm-related genes. In this study, we aimed to identify a small molecule inhibitor of BrpT to combat biofilm formation.
View Article and Find Full Text PDFJ Extracell Vesicles
October 2024
School of Medicine, Sun Yat-Sen University, Shenzhen, China.
Bacterial infections, especially those caused by multidrug-resistant pathogens, pose a significant threat to public health. Vaccines are a crucial tool in fighting these infections; however, no clinically available vaccine exists for the most common bacterial infections, such as those caused by Pseudomonas aeruginosa. Herein, a multiantigenic antibacterial nanovaccine (AuNP@HMV@SPs) is reported to combat P.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!